Breaking News, Collaborations & Alliances

Vical Earns Merck Milestone

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Vical, Inc. received a $1.0 million milestone payment from Merck based on Merck’s planned initiation of a Phase I trial of an investigational plasmid DNA (pDNA) cancer vaccine. The vaccine is based on Vical’s DNA gene delivery technology and encodes human telomerase reverse transcriptase (hTERT), which is the subject of a separate license agreement.     “The breadth of applications for Vical’s gene delivery technology continues to grow, and now encompasses vaccine cand...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters